NCT00415779View on ClinicalTrials.gov

ZANTE: Zometa and Taxotere in Hormone Refractory Prostate Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

July 31, 2006

Primary Completion Date

December 31, 2008

Study Completion Date

July 31, 2009

Conditions
Metastatic Prostate Cancer
Interventions
DRUG

docetaxel

given IV in subsequent cohorts of patients at 30, 40, or 50mg/m2

DRUG

zoledronic acid

2 mg IV every 2 weeks

Trial Locations (2)

80131

Istituto Nazionale dei Tumori, Napoli

Unknown

Ospedale Oncologico Regionale C.R.O.B. - Basilicata, Rionero in Vulture

All Listed Sponsors
lead

National Cancer Institute, Naples

OTHER

NCT00415779 - ZANTE: Zometa and Taxotere in Hormone Refractory Prostate Cancer | Biotech Hunter | Biotech Hunter